SPRB Stock Analysis
SP
Uncovered
Spruce Biosciences Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Spruce Biosciences, Inc operates as a late-stage biopharmaceutical company, which focuses on the development of novel therapies for rare diseases affecting the endocrine system. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-09. The firm is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The firm is also developing Tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. The firm has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with poor disease control and anticipate topline. The company has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH with good disease control focused on glucocorticoid reduction and anticipate topline.